NGGT Inc.

NGGT Inc. is a pioneering gene therapy company leading the charge in developing innovative treatments for genetic disorders. With our groundbreaking projects, NGGT001 for Biett’s Crystaline Dystrophy (BCD) and NGGT002 for Phenylketonuria (PKU) , both granted Orphan Drug Designation (ODD) by the FDA and cleared for Phase I/II clinical trials, we are at the forefront of medical innovation. What sets us apart is our state-of-the-art cGMP facilities, equipped with cutting-edge technology, allowing us to produce all our products for clinical trials in-house. This vertical integration ensures rigorous quality control and accelerates the development timeline, bringing us closer to providing life-changing therapies to patients worldwide. At NGGT Inc., we are driven by our commitment to revolutionize healthcare through the power of gene therapy.